EUVIMEDEUVIMED entdecken
Crossref

Novel Isoidide Subunit-Containing Xanthine Oxidase Inhibitors with Potent Hypouricemic Effects

Xiaoyi Zeng, Yu Chen, Bing Xu, Jie Zhang, Kun Huang, Yangyang Meng, Jiajia Lu, Lihui Wang iD, Mingze Qin iD

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c02404 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Xiaoyi Zeng und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China. Hauptthemen laut MEDLINE: Xanthine Oxidase, Hyperuricemia, Enzyme Inhibitors, Gout Suppressants. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Shenyang Pharmaceutical University, National Natural Science Foundation of China, Natural Science Foundation of Liaoning Province for Excellent Young Scholars.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gout is one of the most common inflammatory arthritic diseases. Clinically, the need for safer and more effective xanthine oxidase (XO) inhibitors remains unmet. Here, a novel series of isoidide subunit-containing XO inhibitors was developed through structural optimization of febuxostat. Compounds Z23-Z26 and Z28-Z30 exhibited potent in vitro XO inhibitory activity, with IC50 values ranging from 0.5 to 2.2 nM. Subsequent assessments of metabolic stability in liver microsomes from multiple species and hypouricemic effects in animal models led to the identification of Z29 as the most promising compound. It exhibited significant XO inhibition and outstanding serum uric acid (SUA)-lowering efficacy in both mouse and rat acute hyperuricemia models. Furthermore, Z29 showed no toxicity to vascular cells in vitro and demonstrated a favorable safety profile in in vivo evaluations of acute toxicity and cardiotoxicity. These findings highlight Z29 as a promising therapeutic candidate for hyperuricemia and gout.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Xanthine OxidaseHyperuricemiaEnzyme InhibitorsGout SuppressantsAnimalsRatsMiceHumansMaleStructure-Activity RelationshipUric AcidMicrosomes, LiverRats, Sprague-DawleyFebuxostat

Substanzen

Xanthine OxidaseEnzyme InhibitorsUric AcidGout SuppressantsFebuxostat

Autor:innen und Institutionen

  • Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University, Shenyang 110016, PR China.
  • Department of Pharmacology, Shenyang Pharmaceutical University, Shenyang 110016, PR China.

ORCID-Profile: Lihui Wang, Mingze Qin

Förderung

  • Shenyang Pharmaceutical University
  • National Natural Science Foundation of China
  • Natural Science Foundation of Liaoning Province for Excellent Young Scholars

Zitieren

APA

Zeng, X., Chen, Y., Xu, B., Zhang, J., Huang, K., Meng, Y., Lu, J., Wang, L., & Qin, M. (2025). Novel Isoidide Subunit-Containing Xanthine Oxidase Inhibitors with Potent Hypouricemic Effects. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c02404

Vancouver

Zeng X, Chen Y, Xu B, Zhang J, Huang K, Meng Y, et al. Novel Isoidide Subunit-Containing Xanthine Oxidase Inhibitors with Potent Hypouricemic Effects. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c02404

BibTeX
@article{Zeng2025,
  author = {Zeng, Xiaoyi and Chen, Yu and Xu, Bing and Zhang, Jie and Huang, Kun and Meng, Yangyang and Lu, Jiajia and Wang, Lihui and Qin, Mingze},
  title = {Novel Isoidide Subunit-Containing Xanthine Oxidase Inhibitors with Potent Hypouricemic Effects},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c02404}
}
Kostenlos starten →